Michimich.com - Investor Workshop at Mar-A-Lago, Million for Acquisitions and Drug Treatment of Suicidal Depression: NRx Pharmaceuticals, Inc. (Stock S: NRXP)

Trending...

Roofman USA Expands Roofing Services Across Michigan, Adding Key Locations - 173
Green Office Partner Named #1 Best Place to Work in Chicago by Crain's for 2025 - 160
"Leading From Day One: The Essential Guide for New Supervisors" Draws from 25+ Years of International Management Experience - 151

$NRXP $31 Price Target from Respected Investment Analyst D. Boral Capital

MIAMI - Michimich -- Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain.

Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression

Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC).

Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations

Kadima Neuropsychiatry Institute Targeted as First Acquisition for HOPE Subsidiary International Network of Interventional Psychiatry Clinics.

Completion of NDA Filing Expected in First Quarter of 2025

NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain

NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

Intravenous ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product; the only treatment currently approved by the FDA is electroconvulsive therapy (ECT). According to the CDC, 3.8 million Americans make a plan for suicide each year. This represents a $3-5 billion market at expected pricing. Based on the data in the trials referenced above, the Company's regulatory counsel encouraged the Company to file an NDA for suicidal depression for NRX-100.

More on Michimich.com

In a January 2025 report, respected investment analysis firm D. Boral Capital assigned NRXP a $31 Price Target. The full report may be viewed at this link:

https://www.nrxpharma.com/wp-content/uploads/2025/01/HOPE-Therapeutics-Advances-With-Kadima.pdf.

Investor Workshop at the Mar-A-Lago Club

On January 10th NRXP announced it conducted an investor workshop to support planned expansion of subsidiary HOPE's network of interventional psychiatry practices focused on the treatment of suicidal depression and PTSD, at the Mar-A-Lago Club in Palm Beach, FL.

The event was attended by Qualified Institutional Buyers as defined by the Securities and Exchange Commission and included Jonathan Javitt, MD, MPH, Chairman and CEO of NRXP together with Dallas Sauer, Founder of Smith and Sauer, the private investment firm that recently committed to invest in both NRXP and HOPE.

Key areas of investor discussions included:

NRXP HOPE's mission to build an international network of best-in class, EBITDA positive, interventional psychiatry clinics

$25 million financing committed by Smith and Sauer (JGS Holdings LLC) to leverage anticipated bank financing projected to secure $100 million in HOPE clinic revenue stream on a pro-forma basis

Recently announced progress for NRXP HOPE's initial clinic acquisitions

Potential mechanisms for follow-on non-dilutive financing to expand NRXP HOPE's network by an additional 50 clinics in 2026 and 100 clinics in 2027

NRXP has been invited to return to Mar-A-Lago for an expanded meeting during the last week of January that will include both Qualified Institutional Buyers and Accredited Investors.

Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations

On January 6th NRXP announced signing of a Binding Term Sheet with Smith & Sauer, LLC, for $25 million equity purchases to fund planned HOPE clinic subsidiary acquisitions. Company management anticipates this new capital in combination with anticipated bank and/or bond lending, to be sufficient to drive substantial revenue in HOPE clinic acquisition during 2025. An additional $2 million equity investment in NRXP will be used to advance the Company's new drug applications for NRX-100 and NRX-101.

Benefits of this agreement include:

More on Michimich.com

Anticipated capital from funds managed by Smith & Sauer to augment potential bank-financing for acquisition of HOPE Therapeutics clinics and support NRXP operations.

Purchase of $25 million in Series A Preferred Stock in HOPE Therapeutics (non-dilutive to NRXP shareholders) convertible into 1/3 of fully diluted HOPE Therapeutics equity, with a 15% current preferred dividend (non-callable for 2 years) for planned HOPE clinic acquisitions.

Purchase $2 million in NRXP equity, above the most recent closing price, at $2.75 per share. Investor will also purchase 500,000 NRXP shares from existing shareholders for $2.75 per share

In connection with both investments, investor shall receive warrants to purchase 3 million currently unregistered shares of NRXP common stock at $3.00 per share with a 24-month term.

Smith & Sauer will also be entitled to receive royalties on net revenues from NRXP product sales to a defined rate of return

Investment in HOPE Therapeutics is expected to enhance the NRXP balance sheet value, strengthening its financial position.

Smith & Sauer to join the HOPE Therapeutics and NRx Pharmaceuticals' Boards of Directors

Kadima Neuropsychiatry Institute Expected First Acquisition for HOPE Subsidiary International Network of Interventional Psychiatry Clinics

On January 2nd NRXP announced the planned acquisition of the Kadima Neuropsychiatry Institute of La Jolla, CA, per the previously announced Letter of Intent, for the Company's HOPE subsidiary network. Kadima is expected to serve as the flagship clinic for HOPE's planned international network of interventional psychiatry clinics, designed to provide advanced treatments for debilitating diseases such as depression, anxiety and PTSD.

Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression

On December 30th NRXP announced the transmission of first section of its New Drug Application (NDA) for NRX-100 (ketamine) for electronic filing with the U.S. Food & Drug Administration (FDA). NRX-100 was initially granted Fast Track Designation in 2017 for use in combination with NRX-101 (D-cycloserine/lurasidone) for treatment of suicidal bipolar depression.

For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/

Media Contact
Company Name: NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP)
Contact Person: Matthew Duffy, Chief Business Officer
Company Website: https://www.nrxpharma.com/
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Home Country: United States

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website